Literature DB >> 14535944

Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain.

Kun Zou1, Daesung Kim, Atsuko Kakio, Kyunghee Byun, Jian-Sheng Gong, Jaewoo Kim, Myeungju Kim, Naoya Sawamura, Sei-ichi Nishimoto, Katsumi Matsuzaki, Bonghee Lee, Katsuhiko Yanagisawa, Makoto Michikawa.   

Abstract

Previously, we found that amyloid beta-protein (Abeta)1-42 exhibits neurotoxicity, while Abeta1-40 serves as an antioxidant molecule by quenching metal ions and inhibiting metal-mediated oxygen radical generation. Here, we show another neuroprotective action of nonamyloidogenic Abeta1-40 against Abeta1-42-induced neurotoxicity in culture and in vivo. Neuronal death was induced by Abeta1-42 at concentrations higher than 2 microm, which was prevented by concurrent treatment with Abeta1-40 in a dose-dependent manner. However, metal chelators did not prevent Abeta1-42-induced neuronal death. Circular dichroism spectroscopy showed that Abeta1-40 inhibited the beta-sheet transformation of Abeta1-42. Thioflavin-T assay and electron microscopy analysis revealed that Abeta1-40 inhibited the fibril formation of Abeta1-42. In contrast, Abeta1-16, Abeta25-35, and Abeta40-1 did not inhibit the fibril formation of Abeta1-42 nor prevent Abeta1-42-induced neuronal death. Abeta1-42 injection into the rat entorhinal cortex (EC) caused the hyperphosphorylation of tau on both sides of EC and hippocampus and increased the number of glial fibrillary acidic protein (GFAP)-positive astrocytes in the ipsilateral EC, which were prevented by the concurrent injection of Abeta1-40. These results indicate that Abeta1-40 protects neurons from Abeta1-42-induced neuronal damage in vitro and in vivo, not by sequestrating metals, but by inhibiting the beta-sheet transformation and fibril formation of Abeta1-42. Our data suggest a mechanism by which elevated Abeta1-42/Abeta1-40 ratio accelerates the development of Alzheimer's disease (AD) in familial AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14535944     DOI: 10.1046/j.1471-4159.2003.02018.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 2.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

4.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

Review 5.  The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

Authors:  D Puzzo; W Gulisano; O Arancio; A Palmeri
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 6.  Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review.

Authors:  Toshio Ariga; Michael P McDonald; Robert K Yu
Journal:  J Lipid Res       Date:  2008-03-11       Impact factor: 5.922

7.  Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42.

Authors:  Hiromi M Sanders; Robert Lust; Jan K Teller
Journal:  Peptides       Date:  2009-02-11       Impact factor: 3.750

8.  The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity.

Authors:  Asad Jan; Ozgun Gokce; Ruth Luthi-Carter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-08-11       Impact factor: 5.157

Review 9.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

10.  Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme.

Authors:  Kun Zou; Tomoji Maeda; Atsushi Watanabe; Junjun Liu; Shuyu Liu; Ryutaro Oba; Yoh-ichi Satoh; Hiroto Komano; Makoto Michikawa
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.